U.K. stocks turn Brexit into boost, on track for best

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
U.K. stocks turn Brexit into boost, on track for best quarter since 2013
Brexit, what Brexit?

In the first full calendar quarter that followed the U.K.’s vote to leave the European Union, the country’s benchmark stock index is set to bang out its best quarterly performance in more than three years, defying fears of a stock market meltdown.

With only one trading day left in the quarter, the FTSE 100 index UKX, -0.94% is up 5.4% for the period, marking its best three-month climb since March 2013. In comparison, the pan-European Stoxx Europe 600 index SXXP, -0.94% is up 2.9%, while the U.S. benchmark S&P 500 index SXP, +1.21% is eyeing a 2.5% third-quarter advance.

“A lot of investors were very shocked after Brexit and worried about the effect on U.K. activity, but interestingly enough the FTSE 100 is not fully reflecting the U.K. economy. The FTSE 250 is much more driven by domestic developments,” said Emmanuel Cau, global equity strategist at J.P. Morgan.

“There was an initial shock in the market, but the falling currency ended up being a big positive for the FTSE,” he added.

The pound has slumped more than 10% against other major currencies following the June 23 vote, giving U.K. companies that make a large chunk of their earnings overseas an unexpected boost.

About 75% of revenue for the FTSE 100 are generated outside the U.K. from large international companies such as AstraZeneca PLC AZN, -1.14% AZN, -2.28% British American Tobacco PLC BATS, -0.15% BTI, -1.08% and Associated British Food PLC ABF, -1.73%

Several companies, including ABF and Burberry PLC BRBY, +1.11% BURBY, -4.04% have already lifted their 2016 profit expectations because of the weak sterling post the Brexit vote.

The FTSE 250 index MCX, -0.91% , which is made up of smaller, more U.K.-exposed companies, dropped sharply in the immediate aftermath of the EU referendum, but rebounded in the third quarter. The benchmark was on track for an 8.8% jump for the period.
Only game in town

But there’s more to the FTSE’s strong quarter than the currency story. Aggressive monetary easing from the Bank of England, ultralow global bond yields and a rebound in commodity prices and emerging markets have together formed the perfect base for a stock rally, analysts said.

“There’s nothing whatsoever in the so-called Brexit uncertainty that would deter me from investing in the stock market. Look at the dividend yield on the FTSE, it’s about 4%. In a low interest-rate world that’s a fairly decent return” said Michael Hewson, chief market analyst at CMC Markets.

“When you look at the spread between gilts and equities, ultimately equities are the only game in town,” he said. Gilts are U.K. government bonds.

Yields on 10-year U.K. government bonds TMBMKGB-10Y, -3.75% plunged to record lows during the quarter, after the U.K. central bank announced plans to restarts its asset-purchase program in a bid to weather any Brexit-related weakness. The bank also said it would start buying corporate bonds, sending yields on such papers to all-time lows.
FTSE ‘ticks all the boxes’

The big question for the FTSE now is whether it can keep the upper hand and continue to rally in the fourth quarter and 2017.

“Yes, we think so,” said Cau from J.P. Morgan said. “It’s cheap and underowned. We think earnings will grow next year because of the [currency] weakness and the commodity composition and to some extent this is the kind of market that should perform well if bond yields stay as low as they are now.”

“The U.K. market ticks all the boxes,” he said.

Cau struck a particularly upbeat tone on the U.K.’s energy companies, forecasting double-digit earnings growth for the sector next year. That’s partly because they come from a low base, and partly because of the recent rebound in oil prices.

The FTSE 100 is heavily skewed toward the commodity sector, so the fortunes of oil and metals tend to drive the market’s performance. Crude oil CLX6, -0.25% is up 29% so far in 2016, and was given a 5.3% boost on Wednesday when the Organization of the Petroleum Exporting Countries, in a surprise move, announced a plan to cut production.

However, investors are skeptical the plan—yet to be completed at the cartel’s November meeting—will actually be carried out by the member states that have been aggressively competing for market share.

“But I think it is definitely a step in the right direction that this supply issue is being addressed. That might help oil prices rise on the short term and help the oil companies in the U.K. market,” Cau said.

The oil rally earlier this week helped the FTSE close at a six-week high on Thursday at 6,919.42. The benchmark, however, slumped 0.9% on Friday as mounting fears over Deutsche Bank DBK, -4.32% DBK, +3.27% DB, +0.87% financial health spread to the U.K. banking sector.




Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 5

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

CAPREIT Welcomes Francine Moore to Board of Trustees

Updated Category News Views 162

CAPREIT Welcomes Francine Moore to Board of Trustees CAPREIT is excited to share that Ms. Francine Moore has been appointed as a new member of its Board of Trustees. This appointment took effect on November 7. Francine is known for her significant experience in the real estate sector, where she has built a remarkable career. Ms. Moore's Impressive Background With over 25...

Continue Reading
Cimpress Sees Target Adjustments Yet Remains Strong – A Deeper Look

Updated Category News Views 95

Cimpress Stock Target Adjustments and Outlook Recently, Truist Securities made notable adjustments to the stock price target for Cimpress N.V. (NASDAQ: CMPR), a recognized leader in mass customization solutions. The new target is now set at $110.00, reduced from the previous $120.00. Despite this adjustment, the firm has reiterated a Buy rating, showcasing confidence in...

Continue Reading
Significant Shift in NICUs: Embracing Prolacta's Innovations

Updated Category News Views 131

Transforming Neonatal Care with Prolacta's Nutritional Innovations Prolacta Offers the Only Nutritional Products Free From Cow Milk and Added Synthetic Ingredients for Extremely Premature Infants in the U.S. In an exciting development for neonatal care, Prolacta Bioscience® has reported that in 2025, the majority of Level III and IV neonatal intensive care units (NICUs)...

Continue Reading
Orchestry Unveils Automated Workspace Solutions for Microsoft 365

Updated Category News Views 127

Orchestry Launches Innovative Workspace Review for Teams and SharePoint Orchestry has introduced a groundbreaking feature that aims to transform the way IT administrators manage collaboration workspaces within Microsoft 365. This new capability, known as Workspace Review, not only automates the maintenance of these workspaces but also enhances security and compliance...

Continue Reading
The Investment Journey of Webster Financial Over Five Years

Updated Category News Views 151

Understanding Webster Financial's Growth Over the Years Webster Financial (NYSE: WBS) has demonstrated remarkable performance in the stock market, consistently outperforming many competitors. Over the past five years, it has achieved an impressive average annual return of 15.04%, surpassing the market by 1.25% annually. This impressive growth reflects the ongoing...

Continue Reading